An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza in Subjects With Post-surgical Neuropathic Pain
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Capsaicin (Primary) ; Capsaicin (Primary) ; Capsaicin (Primary)
- Indications Neuropathic pain; Postoperative pain
- Focus Registrational; Therapeutic Use
- Acronyms AV001
- Sponsors Averitas Pharma
- 05 Dec 2023 Planned End Date changed from 1 Apr 2024 to 1 May 2025.
- 05 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Oct 2024.
- 10 Aug 2021 According to a Grunenthal media release, the completion and subsequent supplemental new drug application submission are expected in 2024.